Catheter ablation of ventricular tachycardias in patients with ischemic cardiomyopathy: validation of voltage mapping criteria for substrate modification by myocardial viability assessment using FDG PET

Catheter ablation of ventricular tachycardia: strategies to improve outcomes

Catheter ablation of ventricular arrhythmias has evolved considerably since it was first described more than 3 decades ago. Advancements in understanding the underlying substrate, utilizing pre-procedural imaging, and evolving ablation techniques have improved the outcomes of catheter ablation. Ensuring safety and efficacy during catheter ablation requires adequate planning, including analysis of the 12 lead ECG and appropriate pre-procedural imaging. Defining the underlying arrhythmogenic substrate and disease eitology allow for the developed of tailored ablation strategies, especially for patients with non-ischemic cardiomyopathies. During ablation, the type of anesthesia can affect VT induction, the quality of the electro-anatomic map, and the stability of the catheter during ablation. For high risk patients, appropriate selection of hemodynamic support can increase the success of VT ablation. For patients in whom VT is hemodynamically unstable or difficult to induce, substrate modification strategies can aid in safe and successful ablation. Recently, there has been an several advancements in substrate mapping strategies that can be used to identify and differentiate local late potentials. The incorporation of high-definition mapping and contact-sense technologies have both had incremental benefits on the success of ablation procedures. It is crucial to harness newer technology and ablation strategies with the highest level of peri-procedural safety to achieve optimal long-term outcomes in patients undergoing VT ablation.

Metabolic heterogeneous zone assessed by 18 FDG-PET is predictive of postablation mortality in patients with ventricular tachycardia

PURPOSE

We sought to study the predictive value of the metabolic heterogeneous zone (HZ) as determined by ¹⁸ Fluorodeoxyglucose (¹⁸ FDG) positron emission tomography (PET) viability studies in ventricular tachycardia (VT) patients.

METHODS

PET studies utilizing ⁸² Rubidium (⁸² Rb) tracer for perfusion and ¹⁸ FDG tracer for viability were analyzed using PMOD (PMOD Technologies) and further analyzed using 684-segment plots. ¹⁸ FDG uptake was normalized to the area with maximal perfusion on the rest ⁸² Rb study. Metabolic scar, HZ, and healthy segments were defined with perfusion-normalized ¹⁸ FDG uptake between 0%-50%, 50%-70%, and >70%, respectively.

RESULTS

Thirty-four VT patients (age, 63 ± 12 years) were evaluated with ¹⁸ FDG-PET viability study. Most (n = 31) patients underwent VT ablation. Patients were categorized to HZ < median versus HZ ≥ median based on a median HZ area size of 21.0 cm² . HZ size was significantly larger in the deceased group than the alive group (35.2 cm² vs. 18.1 cm² , p = .01). Deaths were significantly higher in HZ ≥ 21 cm² group than HZ < 21 cm² group (58.8% vs. 11.8%, p = .005). Survival analysis showed significantly higher mortality in the HZ ≥ 21 cm² group than the HZ < 21 cm² group (HR = 4.1, 95% CI: 1.3-12.6, p = .016). In a multivariable analysis, HZ was found to be an independent predictor for all-cause mortality (HR = 1.07, 95% CI: 1.02-1.12, p = .01) CONCLUSIONS: Increased HZ size of myocardium was associated with increased mortality. Metabolic HZ quantification may be of value in risk stratification and management of ischemic and nonischemic patients with VT.

Metabolic Scar Assessment with 18F-FDG -PET: Correlation to Ischemic VT Substrate and Successful Ablation Sites

Background: Functional/molecular imaging characteristics of ischemic ventricular tachycardia (VT) substrate are incompletely understood. Objective: Compare regional ¹⁸F-FDG - PET tracer uptake with detailed electroanatomic maps (EAM) in a more extensive series of post-infarction VT patients to define metabolic properties of the VT substrate/successful ablation sites. Methods: 3D metabolic left ventricular (LV) reconstructions were created from perfusion-normalized ¹⁸F-FDG images in consecutive patients undergoing VT ablation. Metabolic defects were defined as severe (<50% uptake) or moderate (50-70% uptake) referenced to the maximal 17-segmental uptake. Color-coded PET scars reconstructions were co-registered with corresponding high-resolution 3D EAM. Results: All 56 patients had ischemic cardiomyopathy (EF=29±12%). Severe PET defect (<50%) was larger than EAM voltage scar (<0.5mV) with 63.0±48.4cm² vs. 13.8±33.1cm² (p<0.001). Similarly, moderate/severe PET defect (‎≤‎70%) was larger than areas with abnormal voltage (≤1.5mV) measuring 105.1±67.2cm² vs. 56.2±62.6cm² (p<0.001). Analysis of bipolar voltage (n = 23,389 mapping-points) showed decreased voltage among PET <50% (n = 10,364; 0.5±0.3mV) to PET 50-70% (n = 5,243; 1.5±0.9mV, p<0.01) with normal voltage among PET normal areas >70% (n = 7,782, 3.2±1.3mV, p<0.001). Eighty-eight percent of VT channel/exit sites (n = 44) were metabolically abnormal (PET <50%: 78%; PET 50-70%: 10%), while 12% (n = 6) were in metabolically normal areas (PET>70%). Metabolic channels (n = 26) existed in 45% (n = 25) of patients with average length/width of 17.6±12.5mm/10.3±4.2mm. Metabolic channels were oriented apex/base (86%) predominantly, harboring VT channel/exit sites in 31%. Metabolic Rapid Transition Areas (RTA: >50% change of ¹⁸F-FDG tracer uptake/15mm) were detected in 59% (n = 33) co-localizing to VT channels/exit sites (15%) or its proximity (85%, 12.8±8.5mm). Metabolism-voltage mismatches (MVM) with PET<50%/voltage>1.5mV) were seen in 21% (n = 12) harboring VT channel/exit sites in 41% of patients. Conclusion: Abnormal ¹⁸F-FDG uptake categories can be detected using incremental 3D step-up reconstructions. They predicted decreasing bipolar voltages and VT channel/exit sites in ~90%. Additionally, functional imaging allowed detecting novel molecular tissue characteristics within the ischemic VT substrate such as metabolic channels, RTA, and MVM demonstrating intra-substrate heterogeneity and providing possible targets for imaging-guided ablation.

Substrate Mapping and Ablation for Ventricular Tachycardia in Patients with Structural Heart Disease: How to Identify Ventricular Tachycardia Substrate

Catheter ablation for ventricular tachycardia (VT) has been increasingly used over the past two decades in patients with structural heart disease (SHD). In these individuals, a substrate mapping strategy is being more commonly applied to identify targets for VT ablation, which has been shown to be more effective versus targeting mappable VTs alone. There are a number of substrate mapping methods in existence that aim to explore potential VT isthmuses, although their success rates vary. Most of the reported electrogram-based mapping studies have been performed with ablation catheters; meanwhile, the use of multipolar mapping catheters with smaller electrodes and closer interelectrode spacing has emerged, which allows for an assessment of detailed near-field abnormal electrograms at a higher resolution. Another recent advancement has occurred in the use of imaging techniques in VT ablation, particularly in refining the substrate. The goal of this paper is to review the key developments and limitations of current mapping strategies of substrate-based VT ablation and their outcomes. In addition, we briefly summarize the role of cardiac imaging in delineating VT substrate.

Impact of New Technologies and Approaches for Post-Myocardial Infarction Ventricular Tachycardia Ablation During Long-Term Follow-Up

BACKGROUND

During the past years, many innovations have been introduced to facilitate catheter ablation of post-myocardial infarction ventricular tachycardia. However, the predictors of outcome after ablation were not thoroughly studied.

METHODS AND RESULTS

From 2009 to 2013, consecutive patients referred for post-myocardial infarction ventricular tachycardia ablation were included. The end point of the procedure was complete elimination of local abnormal ventricular activities (LAVA) and ventricular tachycardia (VT) noninducibility. The predictors of outcome with primary end point of VT recurrence were assessed. A total of 125 patients were included (age: 64±11 years; 7 women) for 142 procedures. The left ventricle was accessed via transseptal, retrograde aortic, and epicardial approaches in 87%, 33%, and 37% of patients, respectively. Three-dimensional electroanatomical mapping system was used in 70%, multipolar catheter in 51%, and real-time image integration in 38% (from magnetic resonance imaging in 39% and multidetector computed tomography in 93%) of patients. Before ablation, VT was inducible in 75%, and endocardial/epicardial LAVA were present in 88%/75%. After ablation, complete LAVA elimination was achieved in 60%, and VT noninducibility in 83%. During a median follow-up of 850 days (interquartile range, 439-1707), VT recurrence was observed in 36%. Multivariable analysis identified 3 independent outcome predictors: the ability to achieve complete LAVA elimination (R(2)=0.29; P<0.0001; risk ratio=0.52 [0.38-0.70]), the use of real-time image integration (R(2)=0.21; P=0.0006; risk ratio=0.49 [0.33-0.74]), and the use of multipolar catheters (R(2)=0.08; P=0.05; risk ratio=0.75 [0.56-1.00]).

CONCLUSIONS

Achievement of complete LAVA elimination and use of scar integration from imaging and multipolar catheters to focus high-density mapping are independent predictors of VT-free survival after catheter ablation for post-myocardial infarction ventricular tachycardia.

Substrate mapping strategies for successful ablation of ventricular tachycardia: a review

Catheter ablation of ventricular tachycardia (VT) currently has an important role in the treatment of incessant ventricular tachycardia and reduction of the number of episodes of recurrent ventricular tachycardia. Conventional mapping techniques require ongoing tachycardia and haemodynamic stability during the procedure. However, in many patients with scar-related ventricular tachycardia, non-inducibility of clinical tachycardia, poor induction reproducibility, haemodynamic instability, and multiple ventricular tachycardias with frequent spontaneous changes of morphology, preclude tachycardia mapping. To overcome these limitations, new strategies for mapping and ablation in sinus rhythm (SR) - substrate mapping strategies - have been developed and are currently used by many centres. This review summarizes the progresses recently achieved in the ablative treatment of ventricular tachycardia using a substrate mapping approach in patients with structural heart disease.

Contemporary Mapping Techniques of Complex Cardiac Arrhythmias - Identifying and Modifying the Arrhythmogenic Substrate

Cardiac electrophysiology has moved a long way forward during recent decades in the comprehension and treatment of complex cardiac arrhythmias. Contemporary electroanatomical mapping systems, along with state-of-the-art technology in the manufacture of electrophysiology catheters and cardiac imaging modalities, have significantly enriched our armamentarium, enabling the implementation of various mapping strategies and techniques in electrophysiology procedures. Beyond conventional mapping strategies, ablation of complex fractionated electrograms and rotor ablation in atrial fibrillation ablation procedures, the identification and modification of the underlying arrhythmogenic substrate has emerged as a strategy that leads to improved outcomes. Arrhythmogenic substrate modification also has a major role in ventricular tachycardia ablation procedures. Optimisation of contact between tissue and catheter and image integration are a further step forward to augment our precision and effectiveness. Hybridisation of existing technologies with a reasonable cost should be our goal over the next few years.